力生製藥(002393.SZ):醫藥集團不再為公司間接控股股東
格隆匯7月24日丨力生製藥(002393.SZ)公佈,2019年10月31日,公司間接控股股東天津市醫藥集團有限公司(下稱“醫藥集團”)與天津渤海國有資產經營管理有限公司(下稱““渤海國資”)簽署了《津聯集團有限公司100%股權無償劃轉協議》;同日,金鼎控股與天津醫藥集團國際控股有限公司(下稱““醫藥集團BVI公司”)簽署了《隆騰有限公司33%股權無償劃轉協議》。
上述兩項劃轉協議中分別約定,醫藥集團將其持有的津聯集團100%股權無償劃轉至渤海國資;同時,金鼎控股將其持有的隆騰有限公司33%股權無償劃轉至醫藥集團BVI公司。
2020年7月24日,公司收到醫藥集團通知,津聯集團的股東名冊變更手續已於2020年7月23日於香港辦理完畢。至此,該次無償劃轉已完成。渤海國資仍是力生製藥的間接控股股東,醫藥集團不再是力生製藥的間接控股股東。力生製藥的控股股東、實際控制人均未發生變化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.